Model portefeuille
Rendement portefeulle
+12.035 %

Rendement AEX
+33.325 %

Startdatum
01-01-2009

Startwaarde portefeuille € 74082.37

Startwaarde AEX
€ 245.94


Laatste update:
29-01-2010

DSM reports Q1 2017 results

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Beleggingsadvies 02/05/2017 09:31
Highlights
•DSM reports a very strong first quarter
•Sales up 13% to €2,159m, with 9% organic growth
•Adjusted EBITDA up 17% to €345m
•ROCE up 150 bps to 11.3%
•Cash from operating activities up 43% to €196m
•Net profit up 75% to €149m
•Outlook maintained

Key figures and indicators
in € million
Q1 2017 Q1 2016 % change volume price/ mix FX other
Sales 2,159 1,913 13% 6% 3% 3% 1%
Nutrition 1,398 1,250 12% 5% 3% 4% 0%
Materials 701 600 17% 11% 3% 1% 2%
Adjusted EBITDA 345 296 17%
Nutrition 257 225 14%
Materials 113 95 19%
EBITDA 334 271
ROCE (%) 11.3% 9.8%

CEO statement
Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented: "We are pleased to report a very good start to the year, with continued positive momentum in all businesses as we execute on our mid-term strategic and financial ambitions. Nutrition continued to deliver on its objectives with good growth from Animal and Human Nutrition. Materials demonstrated once again the benefit of its focus on specialties. Both businesses achieved strong volume growth, well above the market.

Notwithstanding the current global socio-economic volatility, we are confident that we will be able to deliver against our full-year objectives given our focus on improving our financial performance through our growth initiatives and our extensive and ambitious profit improvement programs. At the same time we continue to manage our business for the longer term by pursuing our innovation-driven growth strategy.”

Outlook 2017
DSM aims to deliver high-single digit percentage Adjusted EBITDA growth and high double-digit basis point ROCE growth in line with the targets set out in its Strategy 2018.

Key figures and indicators
Key figures and indicators
in € million
Q1 2017 Q1 2016 % change YTD Q1 2017 YTD Q1 2016 % change

Sales - Continuing Operations 2,159 1,913 13% 2,159 1,913 13%
Adjusted EDITDA 345 296 17% 345 296 17%
Nutrition 257 225 14% 257 225 14%
Materials 113 95 19% 113 95 19%
Innovation Center 1 1 1 1
Corporate Activities -26 -25 -26 -25
Adjusted EBITDA margin 16.0% 15.5% 16.0% 15.5%
EBITDA 334 271 334 271
Adjusted EBIT 222 185 222 185 20%
EBIT 206 160 206 160
Capital Employed 7,914 7,456
Average Capital Employed 7,901 7,505
ROCE (%) 11.3% 9.8%
Effective tax rate 18.0% 18.5%
Adjusted net profit 163 109 50% 163 109 50%
Net profit - Total DSM
149 85 75% 149 85 75%
Adjusted net EPS
0.92 0.60 53% 0.92 0.60 53%
Net EPS - Total DSM 0.84 0.46 0.84 0.46
Cash Flow 196 137 43% 196 137 43%
Capital Expenditures1 130 99 130 99
Net debt 2,081 2,0702
.

1) Cash, net of customer funding
2 ) Year-end 2016

In this report:
a) ‘Organic sales growth’ is the total impact of volume and price/mix;
b) ‘Total Working Capital’ refers to the total of ‘Operating Working Capital’ and ‘non-Operating Working Capital'

read more on
http://www.dsm.com/corporate/media/informationcenter-news/2017/05/15-17-dsm-q1-2017-results.html

tijd 09.36
De AEX 523.32 2,19 0,42% DSM EUR 66,60 +93ct vol. 245.000



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL